Parathyroid carcinoma · line 2 · Cinacalcet for hypercalcemia of parathyroid carcinoma

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-CINACALCET-HYPERCALCEMIA`

ID	`IND-PARATHYROID-CARCINOMA-2L-CINACALCET`
Type	Indication
Status	reviewed 2026-07-11
Diseases	`DIS-PARATHYROID-CARCINOMA`
Sources	`SRC-NCCN-NET-2025` `SRC-NCCN-THYROID-2025`

Notes

STUB pending clinical co-lead signoff (CHARTER §6.1 — dev-mode- exempted draft content). Re-resection is deliberately NOT wired as a mandatory phase/Surgery FK here because feasibility is patient/anatomy-specific ("where feasible" per the source narrative) rather than a fixed step — see the open Surgery-entity gap noted on IND-PARATHYROID-CARCINOMA-1L-RESECTION. Systemic options beyond cinacalcet (hypercalcemia control) and pembrolizumab (MSI-H/TMB-high subset only — separate Indication) are genuinely limited for this rare disease; no chemotherapy regimen backed by real guideline evidence exists, so none is authored here.

Used By

Algorithms

ALGO-PARATHYROID-CARCINOMA-1L - ALGO-PARATHYROID-CARCINOMA-1L

Disease

DIS-PARATHYROID-CARCINOMA - Parathyroid carcinoma

Regimen

REG-CINACALCET-HYPERCALCEMIA - Cinacalcet for hypercalcemia of parathyroid carcinoma